Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Inclusion Criteria: * Male or female, who is at least 18 years of age or older. * A clinical diagnosis of rosacea. * A Clinician Erythema Assessment (CEA) score of 3 at Screening and at Pre-dose (T0) on Baseline/Day 1. * A Patient Self Assessment-5 (PSA-5) score of 3 at Screening and at Pre-dose (T0) on Baseline/Day 1. * A Patient Self Assessment-11 (PSA-11) score of 5 at Screening and at Pre-dose (T0) on Baseline/Day 1. Exclusion Criteria: * Three (3) or more facial inflammatory lesions. * Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression. * Known allergies or sensitivities to any components of the study medications, including the active gel ingredient, brimonidine tartrate. * Intraocular pressure (IOP) measurement less than 10 mm Hg.